doxorubicin hydrochloride
- Product NDC
- 67184-0623
- Requested package NDC
- 67184-0623-1
- 11-digit product format
- 671840623
- Labeler code
- 67184
- Product ID
- 67184-0623_c0fef14e-9c64-45d9-b2af-e78848559a25
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- doxorubicin hydrochloride
- Dosage form
- INJECTION, SUSPENSION, LIPOSOMAL
- Route
- INTRAVENOUS
- Labeler
- Qilu Pharmaceutical Co., Ltd.
- Application
- ANDA219881
- Marketing category
- ANDA
- Marketing start
- 2026-02-03
- Substance
- DOXORUBICIN HYDROCHLORIDE
- Active strength
- 2 mg/mL
- Pharmacologic classes
- Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A219881-001 | DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | |
| A219881-002 | DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A219881-001 | AB |
| A219881-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A219881-001 | DOXORUBICIN HYDROCHLORIDE | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A219881-002 | DOXORUBICIN HYDROCHLORIDE | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A219881-001 | DOXORUBICIN HYDROCHLORIDE | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A219881-002 | DOXORUBICIN HYDROCHLORIDE | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A219881-001 | DOXORUBICIN HYDROCHLORIDE | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A219881-002 | DOXORUBICIN HYDROCHLORIDE | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A219881-001 | DOXORUBICIN HYDROCHLORIDE | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A219881-002 | DOXORUBICIN HYDROCHLORIDE | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A219881-001 | DOXORUBICIN HYDROCHLORIDE | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A219881-002 | DOXORUBICIN HYDROCHLORIDE | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | 011fe1cb6892… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219881-001 | DOXORUBICIN HYDROCHLORIDE | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219881-002 | DOXORUBICIN HYDROCHLORIDE | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2026-02-03 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A219881-001 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A219881-002 | AB | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A219881-001 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A219881-002 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A219881-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A219881-002 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A219881-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A219881-002 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A219881-001 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A219881-002 | AB | 1 | 011fe1cb6892… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219881-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219881-002 | AB | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- doxorubicin hydrochloride
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| DOXORUBICIN HYDROCHLORIDE | 2 mg/mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 82F2G7BL4E | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| ed634b03-87cf-4a1c-a513-f34196dabd6f | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | Qilu Pharmaceutical Co., Ltd. | ed634b03-87cf-4a1c-a513-f34196dabd6f | 2026-05-06 | Boxed warning, Warnings, Adverse reactions | 219881 ANDA219881 67184-0623-1 67184-0623 67184062301 |
| Doxorubicin Hydrochloride Liposome | DOXORUBICIN HYDROCHLORIDE | Sagent Pharmaceuticals | c8eb4784-36e0-483f-9e5d-af0552e49bb5 | 2026-02-24 | Boxed warning, Warnings, Adverse reactions | 219881 ANDA219881 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 67184-0623-1 | 67184062301 | 1 VIAL, SINGLE-USE in 1 CARTON (67184-0623-1) / 10 mL in 1 VIAL, SINGLE-USE | 2026-02-03 | No | No | Current |